hVIVO Plc (HVO.L) Announced the positive result for the primary endpoint, following completion of analysis of samples by NIAID and additional results from the Phase IIb viral challenge study of FLU-v, (Study 004, NCT03180801). FLU-v is being developed by Imutex Limited, the company's 49% joint venture with the SEEK Group. The primary endpoint was to assess the incidence of MMID which is refined as evidence of viral shedding in nasopharyngeal swab samples and the presence of at least one symptom. The company added that these results together with the previously reported highly statistically significant reduction in symptoms endpoint (p=0.023) and performing better than placebo in a number of other key endpoints is evidence of the vaccine's protective effect.
Login or register to post comments